Anti-Human FGF-22-Anti-Human FGF-22代理/參數(shù)/廠家-一抗-艾美捷科技有限公司

PRODUCT CENTER

一抗

產(chǎn)品中心

當前位置：首頁 > 產(chǎn)品中心 > 免疫學產(chǎn)品 > 一抗

中文名稱: Anti-Human FGF-22

英文名字: Anti-Human FGF-22

供應(yīng)商: ReliaTech

產(chǎn)品貨號: 101-M407

產(chǎn)品報價: ￥詢價/100ug

產(chǎn)品說明書: 點擊查看

購買方式: 90%產(chǎn)品中國有現(xiàn)貨庫存。銀行轉(zhuǎn)賬、電匯、支票、現(xiàn)金，在線支付寶及網(wǎng)銀支付，或直接與我們電話聯(lián)系400-6800-868

產(chǎn)品新聞

背景資料: Fibroblast growth factor 22 (FGF22) is a 23 kDa, non-glycosylated member of the FGF7 subfamily, from the FGF family of heparin-binding growth factors. The human FGF22 precursor is 170 amino acids (aa) in length, and contains a 22 aa signal sequence with a 148 aa mature region (46). The mature region shows a centrally-placed, 120 aa β-trefoil region (aa 43-168) that is characteristic of all FGF family members. Human FGF22 potentially has one alternate splice form. This isoform is 129 aa in length, and shows a 31 aa substitution for the first N-terminal 72 aa of the standard, or long, form. There is no information related to its possible function. Mature human FGF22 is 86% aa identical to mouse FGF22, with the mouse molecule showing a 9 aa deletion at the N-terminus. FGF 22 is synthesized by at least three cell types? keratinocytes, neurons, and skeletal muscle myotubes. In neurons and myotubes, FGF22 is presumed to function as an organizer of the presynaptic apparatus. Expressed by post-synaptic (or target) cells, FGF22 is believed to bind to FGF R2b on the surface of innervating processes, resulting in synaptic vesicle clustering, organization, and neurite branching. Although FGF22 is assumed to be secreted, little can be found in expressing cell culture media. Presumably, it is bound to 34 kDa FGFBP1, which is a molecule described as typically associated with cell membrane proteoglycans. Thus, following secretion, FGF22 could quickly be immobilized by FGFBP1, only to be released at a later time, or aided by FGFBP1 in its interaction with FGF R2b.

應(yīng)用類型: WB, IHC (P)

免疫原: 該Anti-Human FGF-22的詳細信息查看ReliaTech提供的產(chǎn)品說明書。

來源宿主: 該Anti-Human FGF-22的詳細信息查看ReliaTech提供的產(chǎn)品說明書。

反應(yīng)性: 該Anti-Human FGF-22的詳細信息查看ReliaTech提供的產(chǎn)品說明書。

保存建議: 該Anti-Human FGF-22的詳細信息查看ReliaTech提供的產(chǎn)品說明書。溶解建議：Centrifuge vial prior to opening. Reconstitute the antibody with 500 μl sterile PBS and the final concentration is 200 μg/ml.

其他: ReliaTech全稱為受體配體技術(shù)有限公司 (Receptor Ligand Technologies GmbH)，1999年成立，總部位于德國不倫瑞克，是一家后基因組生物技術(shù)公司。ReliaTech主要專注于受體和配體的發(fā)現(xiàn)與研究。此外，ReliaTech也開發(fā)應(yīng)用于血管與淋巴管生成研究的相關(guān)高品質(zhì)試劑。目前ReliaTech提供近2800款產(chǎn)品，產(chǎn)品線主要包括重組蛋白(細胞因子、生長因子、可溶性受體)、抗體、ELISA試劑盒等。